Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France

References

• Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157(1):199–11.
   PubMed Web of Science ®Google Scholar
• Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–440.
   PubMed Web of Science ®Google Scholar
• Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax. 2011;66(6):462–467.
   PubMed Web of Science ®Google Scholar
• Nunes H, Carton Z, Cottin V, et al. Preliminary results of the French national prospective cohort on IPF. Eur Respir J. 2011;38(Suppl 55):646. Available from: https://erj.ersjournals.com/content/38/Suppl_55/p646.
   Google Scholar
• Strand MJ, Sprunger D, Cosgrove GP, et al. Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia. Chest. 2014;146(3):775–785.
   Web of Science ®Google Scholar
• Lee AS, Mira-Avendano I, Ryu JH, et al. The burden of idiopathic pulmonary fibrosis: an unmet public health need. Respir Med. 2014;108(7):955–967.
   Web of Science ®Google Scholar
• Du Bois RM. Idiopathic pulmonary fibrosis: present understanding and future options. Eur Respir Rev. 2011;20(121):132–133.
   Google Scholar
• Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016;47(1):243–253.
   PubMed Web of Science ®Google Scholar
• Taniguchi H, Ebina M, Kondoh Y, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):821–829.
   PubMed Web of Science ®Google Scholar
• King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.
   PubMed Web of Science ®Google Scholar
• Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar
• NICE. Nintedanib for treating idiopathic pulmonary fibrosis (review of TA379) -Committee papers [ID752]. London: NICE; 2015.
   Google Scholar
• Haute Autorité de Santé (HAS). Avis d’efficience - ESBRIET® 267 mg (pirfénidone). Paris: Haute Autorité de santé; 2015.
   Google Scholar
• Haute Autorité de Santé (HAS). Choix méthodologiques pour l’évaluation économique à la HAS 2011. HAS. Available from https://www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf
   Google Scholar
• Cottin V, Crestani B, Valeyre D, et al. French recommendations for idiopathic pulmonary fibrosis: oriented toward practice. Rev Mal Respir. 2013;30(10):814–816.
   Web of Science ®Google Scholar
• Loveman E, Copley VR, Colquitt J, et al. The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation. Nat Inst Health Res. 2015; 19(20):i-xxiv, 1-336.
   Google Scholar
• Du Bois RM, Albera C, Bradford WZ, et al. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2014;43(5):1421–1429.
   PubMed Web of Science ®Google Scholar
• Du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(4):459–466.
   PubMed Web of Science ®Google Scholar
• Loveman E, Copley VR, Scott DA, et al. Comparing new treatments for idiopathic pulmonary fibrosis–a network meta-analysis. BMC Pulm Med. 2015;15:37.
   PubMed Web of Science ®Google Scholar
• Institut National de la Statistique et des Etudes Economiques (INSEE). Bilan démographique 2013; 2013. Available from: https://www.insee.fr/fr/statistiques/12809562014
   Google Scholar
• Agence de biomédecine. Le rapport médical et scientifique de l’Agence de la biomédecine 2014. biomédecine Ad, editor. Paris: Agence de biomédecine; 2014.
   Google Scholar
• Orphanet. Prevalence of rare diseases: bibliographic data. 2014. Available from: https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf.
   Google Scholar
• CNAMTS; ID. Eco-Santé, 2014. Irdes, Drees, Cnamts. Available from: http://www.ecosante.fr/index2.php?base=DEPA&langh=FRA&langs=FRA
   Google Scholar
• Caisse Nationale d’Assurance Maladie (CNAM). Coût des ALD en 2009; 2009. Available from: https://www.ameli.fr/l-assurance-maladie/statistiques-et-publications/donnees-statistiques/affection-de-longue-duree-ald/archives/cout-des-ald-en-2009.php
   Google Scholar
• Costabel U, Albera C, Bradford WZ, et al. Analysis of lung function and survival in RECAP: an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(3):198–205.
   PubMed Web of Science ®Google Scholar
• Kreuter M. Pirfenidone: an update on clinical trial data and insights from everyday practice. Eur Respir Rev. 2014;23(131):111–117.
   PubMedGoogle Scholar
• Thabut G, Mal H, Castier Y, et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg. 2003;126(2):469–475.
   PubMed Web of Science ®Google Scholar
• NICE. Pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282) - Committee papers [ID837]. USA: NICE; 2016.
   Google Scholar
• Porte F, Cottin V, Catella L, et al. Health economic evaluation in idiopathic pulmonary fibrosis in France. Curr Med Res Opin. 2018 Mar 9;2018:1–10.
   Google Scholar
• Fleetwood K, McCool R, Glanville J, et al. Systematic review and network meta-analysis of idiopathic pulmonary fibrosis treatments. J Manag Care Spec Pharm. 2017;2017(23(3–b)):S5–S16.
   Google Scholar
• Ara RBJ. Using health state utility values from the general population to approximate baselines in decision analytic models when conditionspecific data are not available. Value Health. 2011;2011(14):539–545.
   Google Scholar
• Institut National de la Statistique et des Etudes Economiques (INSEE). Indice des prix à la consommation - Base 2015 - Ensemble des ménages - France - Services de santé. INSEE; 2018. [cited 2018 Aug]. Available from: https://www.insee.fr/fr/statistiques/serie/001763845
   Google Scholar
• Haut Conseil pour l’avenir de l’Assurance Maladie (HCAAM). Rapport annuel du HCAAM. Paris, France: HCAAM; 2013.
   Google Scholar
• Direction de la recherche des études de l’évaluation et des statistiques (DREES). Comptes nationaux de la santé (CNS). Paris, France: Ministère des Solidarités et de la Santé; 2012.
   Google Scholar
• Caisse Nationale d’Assurance Maladie (CNAM). Base des médicaments et informations tarifaires (BDM_IT); 2018. [cited 2018 Jul]. Available from: http://www.codage.ext.cnamts.fr/codif/bdm_it/index.php?p_site=AMELI
   Google Scholar
• Caisse Nationale d’Assurance Maladie (CNAM). Classification commune des actes medicaux (CCAM) v54; 2018. [cited 2018 Jul]. Available from: https://www.ameli.fr/accueil-de-la-ccam/telechargement/index.php
   Google Scholar
• Caisse Nationale d’Assurance Maladie (CNAM). Table nationale de codage de biologie (TNB); 2018. [cited 2018 Jul]. Available from: http://www.codage.ext.cnamts.fr/codif/nabm/index_presentation.php?p_site=AMELI
   Google Scholar
• Caisse Nationale d’Assurance Maladie (CNAM). Liste des produits et des prestations (LPP); 2018. [cited 2018 Jul]. Available from: http://www.codage.ext.cnamts.fr/codif/tips/index_presentation.php?p_site=AMELI
   Google Scholar
• Cottin V, Schmidt A, Catella L, et al. Burden of idiopathic pulmonary fibrosis progression: a 5-year longitudinal follow-up study. PLoS One. 2017;12(1):e0166462.
   Web of Science ®Google Scholar
• Agence Technique de l’Information sur l’Hospitalisation (ATIH). Tarifs MCO et HAD; 2018. [cited 2018 Jul]. Available from: https://www.atih.sante.fr/tarifs-mco-et-had
   Google Scholar
• ScanSanté. Activité MCO par GHM ou racine; 2017. [cited 2018 Jul]. Available from: https://www.scansante.fr/applications/statistiques-activite-MCO-par-GHM
   Google Scholar
• Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014;31(4):375–391.
   PubMed Web of Science ®Google Scholar
• Hughes G, Toellner H, Morris H, et al. Real world experiences: pirfenidone and nintedanib are effective and well tolerated treatments for idiopathic pulmonary fibrosis. J Clin Med. 2016;5(9):78.
   PubMed Web of Science ®Google Scholar
• Brunnemer E, Walscher J, Tenenbaum S, et al. Real-world experience with nintedanib in patients with idiopathic pulmonary fibrosis. Respiration. 2018;95(5):301–309.
   PubMed Web of Science ®Google Scholar
• Jouneau S, Gamez AS, Traclet J, et al. A 2-year observational study in patients suffering from idiopathic pulmonary fibrosis and treated with pirfenidone: a French ancillary study of PASSPORT. Respiration. 2019;1–10.
   Web of Science ®Google Scholar
• NICE. Nintedanib for treating idiopathic pulmonary fibrosis NICE. London, UK: 2015.
   Google Scholar
• Rinciog CWM, Chang S, Maher TM 5, et al. Diamantopoulos A. A cost-effectiveness analysis of nintedanib in idiopathic pulmonary fibrosis in the UK. Pharmacoeconomics. 2017;35(4):479–491.
   Web of Science ®Google Scholar
• Anyanwu ACMA, Rogers CA, Murday AJ. Assessment of quality of life in lung transplantation using a simple generic tool. Thorax. 2001;56:218–222.
   Web of Science ®Google Scholar